Skip to content
MedsAcross

Medicine

Aggrastat 12.5 mg/250 mL injection

Tirofiban · Intravenous · Medicure International
Available on requestPrescription onlyUS FDA

Aggrastat 12.5 mg/250 mL injection is a prescription medicine containing Tirofiban for intravenous use, marketed by Medicure International, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Do not freeze. Store AGGRASTAT at controlled room temperature, 25°C (77°F)…

Key facts

Active ingredient (INN)
Tirofiban
Brand
Aggrastat
Strength
12.5 mg/250 mL
Dosage form
Injection
Route
Intravenous
Packs
1 container of 250 mL
Marketing authorisation holder
Medicure International
Manufacturer
Medicure International
Origin register
US FDA, United States
Storage
Do not freeze. Store AGGRASTAT at controlled room temperature, 25°C (77°F) with excursions permitted between 15-30°C (59-86°F). Protect from light during storage.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
B01AC17 Tirofiban
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
14 May 1998
Identifiers
RxCUI 1737466, 1737468, 1737471 +3DailyMed set ID fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f, e850111f-e713-41a2-9c65-21c517cf5511NDC 25208-002, 25208-902Application NDA020913

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 container in 1 carton / 250 mL in 1 container25208-002-02Medicure International14 May 1998
1 container in 1 carton / 250 mL in 1 container25208-902-02Medicure International14 May 1998

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 14 May 1998Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Tirofiban 12.5 mg/250 mL injection.

Compare 1

Other strengths and forms of Tirofiban

Clinical summary

Tirofiban is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). MedsAcross supplies Tirofiban for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Tirofiban

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Aggrastat 12.5 mg/250 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.